1. Home
  2. VSTA vs CHRS Comparison

VSTA vs CHRS Comparison

Compare VSTA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vasta Platform Limited

VSTA

Vasta Platform Limited

N/A

Current Price

$4.95

Market Cap

401.2M

Sector

Real Estate

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.32

Market Cap

186.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTA
CHRS
Founded
1966
2010
Country
Brazil
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
401.2M
186.0M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
VSTA
CHRS
Price
$4.95
$1.32
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.02
AVG Volume (30 Days)
9.9K
943.2K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.16
1.34
Revenue
$326,007,430.00
$277,728,000.00
Revenue This Year
$11.22
N/A
Revenue Next Year
$13.43
$67.29
P/E Ratio
$4.26
$1.05
Revenue Growth
13.60
152.07
52 Week Low
$2.00
$0.71
52 Week High
$5.49
$1.89

Technical Indicators

Market Signals
Indicator
VSTA
CHRS
Relative Strength Index (RSI) 50.23 48.00
Support Level $4.91 $1.34
Resistance Level $4.99 $1.43
Average True Range (ATR) 0.10 0.08
MACD -0.00 0.01
Stochastic Oscillator 88.89 52.36

Price Performance

Historical Comparison
VSTA
CHRS

About VSTA Vasta Platform Limited

Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: